10E8.4/iMab Bispecific Antibody and VRC07-523LS Monoclonal Antibody in HIV-infected Adults

NCT ID: NCT05890963

Last Updated: 2025-04-25

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 20 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-11-28
• Study Completion Date: 2027-05-31

Brief Summary

This is an open-label phase 1b clinical trial enrolling people living with HIV (PLWH) who are antiretroviral therapy (ART)-naïve or have not been on ART for > 24 weeks. This study will enroll PLWH to assess the safety, tolerability, and antiviral effect of bispecific and long-acting bNAbs, alone and in combination. The study will be conducted as a single center study at National Institute for Medical Research-Mbeya Medical Research Center (NIMR-MMRC) in Mbeya, Tanzania.

20 PLWH will be sequentially enrolled into one of 5 arms, each arm comprised of 4 participants. Sequential enrollment will occur in the following order:

• Arm 1 will receive standard daily oral ART.
• Arm 2 will receive a single dose of 10E8.4/iMab 600mg intravenous injection (IV).
• Arm 3 will receive a single dose of 10E8.4/iMab 600mg intramuscular injection (IM).
• Arm 4 will receive a single dose of 10E8.4/iMab 1800mg IV.
• Arm 5 will receive a single dose of combination therapy with both 10E8.4/iMab 1800mg IV and VRC07-523LS 1200mg IV.

Detailed Description

Although global initiatives have made great strides in controlling the human immunodeficiency virus (HIV) pandemic, HIV and acquired immune deficiency syndrome (AIDS) continue to impact the lives and livelihoods of a significant portion of the population. In 2019, 38 million individuals were living with HIV and 690,000 died of AIDS-related causes. Despite extensive global efforts for disease control over the last 20 years, 1.7 million individuals contract HIV annually. Antiretroviral therapy (ART) reduces morbidity and mortality associated with HIV by suppressing viral replication but does not eradicate infection. There are barriers to universal ART use that include toxicities, costs, drug resistance, and the need for lifelong adherence. To overcome these barriers, HIV broadly neutralizing antibodies (bNAbs) represent a novel approach to HIV prevention and treatment.

The primary endpoint of change in viral load will be assessed at day 14. Participants will then transition to Step 2, during which all participants will take standard daily oral ART and have viral load monitored through Step 2 week 48.

Conditions

HIV-1-infection

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm 1: Oral ART

Participants will receive standard daily oral ART.

Group Type: ACTIVE_COMPARATOR

ART

Intervention Type: DRUG

ART is a combination of three or more drugs from different classes of antiretroviral medication.

Arm 2: 10E8.4/iMab 600mg IV.

Participants will receive a single dose of 10E8.4/iMab 600mg IV.

Group Type: EXPERIMENTAL

10E8.4/iMab

Intervention Type: DRUG

10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Arm 3: 10E8.4/iMab 600mg IM.

Participants will receive a single dose of 10E8.4/iMab 600mg IM.

Group Type: EXPERIMENTAL

10E8.4/iMab

Intervention Type: DRUG

10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Arm 4:10E8.4/iMab 1800mg IV.

Participants will receive a single dose of 10E8.4/iMab 1800mg IV.

Group Type: EXPERIMENTAL

10E8.4/iMab

Intervention Type: DRUG

10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Arm 5: Combination 10E8.4/iMab and VRC07-523LS therapy

Participants will receive a single dose of combination therapy with both 10E8.4/iMab 1800mg IV. and VRC07-523LS 1200mg IV.

Group Type: EXPERIMENTAL

10E8.4/iMab

Intervention Type: DRUG

10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

VRC07-523LS

Intervention Type: DRUG

VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.

Interventions

ART

ART is a combination of three or more drugs from different classes of antiretroviral medication.

Intervention Type: DRUG

10E8.4/iMab

10E8.4/iMab is an engineered bispecific antibody with two arms combined into a single molecule that exhibits synergistic enhancement of antiviral activity. 10E8.4/iMab will be administered IV at the 600mg or 1800mg dose or IM at 600mg dose to participants in Step 1 per the Schedule of Events (SOE) based on the arm the participant is assigned.

Intervention Type: DRUG

VRC07-523LS

VRC07-523LS is an engineered variant of VRC01, a bNAb that targets the CD4 binding site of the HIV-1 envelope. VRC07-523LS will be administered IV at the 1200mg dose to participants in Step 1 per the SOE.

Intervention Type: DRUG

Other Intervention Names

antiretroviral therapy; ibalizumab; VRC01 variant

Eligibility Criteria

Inclusion Criteria

1. Able to read and write in Kiswahili and/or English

2. Able and willing to provide written informed consent

3. Passes Test of Understanding (TOU)

4. Aged 18-50 years, inclusive

5. Antiretroviral Therapy (ART)-naïve or no ART for > 24 weeks at the time of screening

6. HIV RNA 1,000-100,000 copies/mL

7. CD4 ≥ 500 cells/mm3

8. Laboratory criteria at screening within protocol-specified limits for blood, chemistry and urinalysis

9. Willing and able to participate in study visits and procedures for up to 50 weeks

10. Willing and able to begin ART as directed during the study

11. Willing and able to use barrier protection during sex with partners without HIV or partners with unknown HIV status throughout Step 1 and until viral suppression <200 copies/mL is confirmed in Step 2

12. Willing and able to adhere to the following contraception requirements:

1. Participants who are able to become pregnant must agree to use at least one method of highly effective contraception if participating in sexual activity that could lead to pregnancy. This must begin at least 14 days prior to study enrollment.

2. Participants who engage in sexual activity that could lead to their partner becoming pregnant and who are of reproductive potential must agree to use a barrier method of contraception to avoid pregnancy in a sexual partner of reproductive potential. The barrier method must be used for the duration of the study.

Exclusion Criteria

1. Weight >100 kg

2. Previous receipt of humanized or human monoclonal antibody whether licensed or investigational (other than for the prevention and/or treatment of SARS-CoV2/COVID-19)

3. History of viral failure on two or more ART regimens

4. Planned or anticipated need for enfuvirtide, maraviroc, fostemsavir, or ibalizumab for antiretroviral therapy.

5. AIDS-defining illness, as enumerated by the WHO Stage 3 or 4, within the six months prior to enrollment

6. Ongoing oral thrush

7. Active injection or other recreational drug use within the previous 12 months that, in the opinion of the investigator, would impede the participant's ability to safely and consistently adhere to the study protocol

8. History of a severe allergic reaction with generalized urticaria, angioedema or anaphylaxis in the 2 years prior to enrollment.

9. History of chronic urticaria requiring daily treatment

10. Known active hepatitis B virus infection or positive hepatitis B surface antigen at any time in the past

11. Known active hepatitis C virus infection or positive hepatitis C antibody at any time in the past

12. Untreated syphilis

13. Estimated GFR < 50 mL/min within the past 90 days

14. Pregnant or breast-feeding

15. Receipt of licensed vaccine or other investigational study agent within 28 days prior to enrollment or any past participation in an investigational HIV vaccine study with receipt of active product

16. Current or planned participation in another interventional clinical trial during the study period, including clinical trials of investigational new drugs or investigating a new application for an approved medication

17. Chronic or recurrent use of medications that modify host immune response, such as oral steroids, parenteral steroids, or cancer chemotherapy (note: locally-acting medications-such as inhaled, topical, or intra-articular steroids-are allowed)

18. Any other chronic or clinically significant medical condition that in the opinion of the investigator would jeopardize the safety or rights of the participant including, but not limited to: diabetes mellitus type I, chronic hepatitis, renal failure; OR clinically significant forms of: drug or alcohol abuse, mental illness, severe asthma, autoimmune disease, decompensated psychiatric disorders, hypertension, heart disease, or cancer

19. Any medications that, in the opinion of the investigator, would preclude intramuscular injections

20. Study site employee

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 50 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Henry M. Jackson Foundation for the Advancement of Military Medicine

OTHER

Sponsor Role: collaborator

US Military HIV Research Program

NETWORK

Sponsor Role: collaborator

National Institute of Allergy and infectious Diseases (NIAID)/Vaccine Research Center (VRC)

UNKNOWN

Sponsor Role: collaborator

David Ho

OTHER

Sponsor Role: lead

Responsible Party

David Ho

Professor of Medicine

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Marco Missanga, MD

Role: PRINCIPAL_INVESTIGATOR

NIMR-MMRC

David D. Ho, MD

Role: PRINCIPAL_INVESTIGATOR

Columbia University Irving Medical Center (IND Sponsor)

Trevor A. Crowell, MD, PhD

Role: STUDY_CHAIR

The U.S. Military HIV Research Program (MHRP)

Locations

National Institute for Medical Research-Mbeya Medical Resarch Center

Mbeya, , Tanzania

Countries

Tanzania

References

Huang Y, Yu J, Lanzi A, Yao X, Andrews CD, Tsai L, Gajjar MR, Sun M, Seaman MS, Padte NN, Ho DD. Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity. Cell. 2016 Jun 16;165(7):1621-1631. doi: 10.1016/j.cell.2016.05.024.

Reference Type: BACKGROUND

PMID: 27315479 (View on PubMed)

Mahomed S, Garrett N, Capparelli EV, Osman F, Harkoo I, Yende-Zuma N, Gengiah TN, Archary D, Samsunder N, Baxter C, Mkhize NN, Modise T, Carlton K, McDermott A, Moore PL, Karim QA, Barouch DH, Fast PE, Mascola JR, Ledgerwood JE, Morris L, Abdool Karim SS. Safety and Pharmacokinetics of Monoclonal Antibodies VRC07-523LS and PGT121 Administered Subcutaneously for Human Immunodeficiency Virus Prevention. J Infect Dis. 2022 Aug 26;226(3):510-520. doi: 10.1093/infdis/jiac041.

Reference Type: BACKGROUND

PMID: 35134995 (View on PubMed)

Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, Imamichi H, Bailer RT, Chakrabarti B, Sharma SK, Alam SM, Wang T, Yang Y, Zhang B, Migueles SA, Wyatt R, Haynes BF, Kwong PD, Mascola JR, Connors M. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012 Nov 15;491(7424):406-12. doi: 10.1038/nature11544. Epub 2012 Sep 18.

Reference Type: BACKGROUND

PMID: 23151583 (View on PubMed)

Burkly LC, Olson D, Shapiro R, Winkler G, Rosa JJ, Thomas DW, Williams C, Chisholm P. Inhibition of HIV infection by a novel CD4 domain 2-specific monoclonal antibody. Dissecting the basis for its inhibitory effect on HIV-induced cell fusion. J Immunol. 1992 Sep 1;149(5):1779-87.

Reference Type: BACKGROUND

PMID: 1380539 (View on PubMed)

Jacobson JM, Kuritzkes DR, Godofsky E, DeJesus E, Larson JA, Weinheimer SP, Lewis ST. Safety, pharmacokinetics, and antiretroviral activity of multiple doses of ibalizumab (formerly TNX-355), an anti-CD4 monoclonal antibody, in human immunodeficiency virus type 1-infected adults. Antimicrob Agents Chemother. 2009 Feb;53(2):450-7. doi: 10.1128/AAC.00942-08. Epub 2008 Nov 17.

Reference Type: BACKGROUND

PMID: 19015347 (View on PubMed)

Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD, Siliciano RF. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science. 1997 Nov 14;278(5341):1295-300. doi: 10.1126/science.278.5341.1295.

Reference Type: BACKGROUND

PMID: 9360927 (View on PubMed)

Wolfe D, Carrieri MP, Shepard D. Treatment and care for injecting drug users with HIV infection: a review of barriers and ways forward. Lancet. 2010 Jul 31;376(9738):355-66. doi: 10.1016/S0140-6736(10)60832-X.

Reference Type: BACKGROUND

PMID: 20650513 (View on PubMed)

Jaworski JP, Cahn P. Preventive and therapeutic features of broadly neutralising monoclonal antibodies against HIV-1. Lancet HIV. 2018 Dec;5(12):e723-e731. doi: 10.1016/S2352-3018(18)30174-7. Epub 2018 Sep 21.

Reference Type: BACKGROUND

PMID: 30245003 (View on PubMed)

Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA, Fauci AS. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):13193-7. doi: 10.1073/pnas.94.24.13193.

Reference Type: BACKGROUND

PMID: 9371822 (View on PubMed)

Other Identifiers

W81XWH-18-2-0040

Identifier Type: OTHER_GRANT

Identifier Source: secondary_id

RV584

Identifier Type: OTHER

Identifier Source: secondary_id

AAAU5207

Identifier Type: -

Identifier Source: org_study_id